News

Clinical trials are set to launch later this year to evaluate whether the cancer drug, PRL3-zumab, is effective in treating wet age-related macular degeneration (AMD) as well as diabetic retinopathy.

Semaglutide, a popular diabetes and weight loss drug, has been found to double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with diabetes.

Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.

Researchers concluded that anti-VEGF treatments do raise the risk of glaucoma progression.

Researchers compared the visual outcomes and rate of intraoperative complications in patients with nAMD and control eyes that did not have nAMD that underwent phacoemulsification cataract surgery o...

Researchers discovered that levodopa is safe, well-tolerated and not only improved visual outcomes but also delayed anti-VEGF injections.